Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study
Introduction - Docetaxel consolidation therapy (DCT) after concurrent cisplatin/docetaxel chemoradiation therapy (CRT) produces high tumor control in non-small-cell lung cancer (NSCLC); toxicity is, however, considerable. We aimed to determine the maximally tolerated dose (MTD) for DCT. - Patients a...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[January 2010]
|
| In: |
Clinical lung cancer
Year: 2010, Jahrgang: 11, Heft: 1, Pages: 45-50 |
| ISSN: | 1938-0690 |
| DOI: | 10.3816/CLC.2010.n.007 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3816/CLC.2010.n.007 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1525730411700377 
|
| Verfasserangaben: | Rudolf M. Huber, Astrid Borgmeier, Michael Flentje, Jochen Willner, Michael Schmidt, Christian Manegold, Peter Bramlage, Jürgen Debus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1846027799 | ||
| 003 | DE-627 | ||
| 005 | 20230710132730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230523s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3816/CLC.2010.n.007 |2 doi | |
| 035 | |a (DE-627)1846027799 | ||
| 035 | |a (DE-599)KXP1846027799 | ||
| 035 | |a (OCoLC)1389794423 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Huber, Rudolf M. |e VerfasserIn |0 (DE-588)1137023066 |0 (DE-627)893961426 |0 (DE-576)491048599 |4 aut | |
| 245 | 1 | 0 | |a Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer |b results of a phase I study |c Rudolf M. Huber, Astrid Borgmeier, Michael Flentje, Jochen Willner, Michael Schmidt, Christian Manegold, Peter Bramlage, Jürgen Debus |
| 264 | 1 | |c [January 2010] | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.05.2023 | ||
| 520 | |a Introduction - Docetaxel consolidation therapy (DCT) after concurrent cisplatin/docetaxel chemoradiation therapy (CRT) produces high tumor control in non-small-cell lung cancer (NSCLC); toxicity is, however, considerable. We aimed to determine the maximally tolerated dose (MTD) for DCT. - Patients and Methods - Patients with inoperable stage IIIB NSCLC received docetaxel 20 mg/m2 and cisplatin 25 mg/m2 on days 1, 8, 15, 22, 29, and 36, with concurrent radiation therapy 5 days per week for a total dose of 66 Gy. Patients achieving stable disease, partial response, or complete response were given DCT on days 71, 92, and 113. DCT was started with 75 mg/m2 and titrated depending on tolerability. The MTD of docetaxel was defined as the dose preceding that at which 3 or more patients experienced dose-limiting toxicity (DLT). - Results - Of 23 patients enrolled (median age, 58.8 years ± 7.3 years), 19 received complete CRT (4 withdrew because of toxicity). Of the patients receiving complete CRT, 1 patient died and 1 became operable, leaving 17 patients eligible for DCT starting at 75 mg/m2. After the third patient with DLT, dose was reduced to 60 mg/m2. Median survival was 27.6 months ± 23.1 months. Median TTP was 12.4 months ± 10.7 months. - Conclusion - The MTD of DCT after concurrent cisplatin/docetaxel CRT was determined to be 60 mg/m2, but toxicity was considerable. The benefit-risk ratio of DCT has, however, been questioned by a placebo-controlled phase III trial. Further phase III trials need to consider further stratification factors (pretreatment forced expiratory volume [FEV]1, hemoglobin, performance, and stage) to define a role for DCT in patients with NSCLC. | ||
| 650 | 4 | |a Dose-limiting toxicity | |
| 650 | 4 | |a Forced expiratory volume | |
| 650 | 4 | |a Hemoglobin | |
| 650 | 4 | |a Maximum tolerated dose | |
| 700 | 1 | |a Borgmeier, Astrid |e VerfasserIn |4 aut | |
| 700 | 1 | |a Flentje, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Willner, Jochen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 700 | 1 | |a Bramlage, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Debus, Jürgen |d 1964- |e VerfasserIn |0 (DE-588)1022671421 |0 (DE-627)717025780 |0 (DE-576)365774944 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lung cancer |d Dallas, Tex. : Cancer Information Group, 1999 |g 11(2010), 1 vom: Jan., Seite 45-50 |h Online-Ressource |w (DE-627)49143846X |w (DE-600)2193644-4 |w (DE-576)358410746 |x 1938-0690 |7 nnas |a Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer results of a phase I study |
| 773 | 1 | 8 | |g volume:11 |g year:2010 |g number:1 |g month:01 |g pages:45-50 |g extent:6 |a Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer results of a phase I study |
| 856 | 4 | 0 | |u https://doi.org/10.3816/CLC.2010.n.007 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1525730411700377 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230523 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 1022671421 |a Debus, Jürgen |m 1022671421:Debus, Jürgen |d 910000 |d 911400 |e 910000PD1022671421 |e 911400PD1022671421 |k 0/910000/ |k 1/910000/911400/ |p 8 |y j | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |d 61800 |e 60000PM108614913 |e 61800PM108614913 |k 0/60000/ |k 1/60000/61800/ |p 6 | ||
| 999 | |a KXP-PPN1846027799 |e 4324777888 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1846027799"],"doi":["10.3816/CLC.2010.n.007"]},"name":{"displayForm":["Rudolf M. Huber, Astrid Borgmeier, Michael Flentje, Jochen Willner, Michael Schmidt, Christian Manegold, Peter Bramlage, Jürgen Debus"]},"physDesc":[{"extent":"6 S."}],"recId":"1846027799","note":["Gesehen am 23.05.2023"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"title":[{"title_sort":"Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer","title":"Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer","subtitle":"results of a phase I study"}],"person":[{"role":"aut","given":"Rudolf M.","family":"Huber","display":"Huber, Rudolf M."},{"display":"Borgmeier, Astrid","family":"Borgmeier","given":"Astrid","role":"aut"},{"family":"Flentje","role":"aut","given":"Michael","display":"Flentje, Michael"},{"display":"Willner, Jochen","family":"Willner","given":"Jochen","role":"aut"},{"display":"Schmidt, Michael","role":"aut","given":"Michael","family":"Schmidt"},{"given":"Christian","role":"aut","family":"Manegold","display":"Manegold, Christian"},{"display":"Bramlage, Peter","family":"Bramlage","role":"aut","given":"Peter"},{"display":"Debus, Jürgen","role":"aut","given":"Jürgen","family":"Debus"}],"relHost":[{"id":{"eki":["49143846X"],"issn":["1938-0690"],"zdb":["2193644-4"]},"part":{"pages":"45-50","extent":"6","text":"11(2010), 1 vom: Jan., Seite 45-50","issue":"1","year":"2010","volume":"11"},"titleAlt":[{"title":"Lung cancer"}],"pubHistory":["1.1999/2000 -"],"title":[{"title":"Clinical lung cancer","title_sort":"Clinical lung cancer"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 04.02.20"],"origin":[{"publisher":"Cancer Information Group","dateIssuedKey":"1999","publisherPlace":"Dallas, Tex.","dateIssuedDisp":"1999-"}],"disp":"Concurrent chemoradiation therapy with Docetaxel/Cisplatin followed by Docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer results of a phase I studyClinical lung cancer","recId":"49143846X","physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"[January 2010]"}]} | ||
| SRT | |a HUBERRUDOLCONCURRENT2010 | ||